Chronic Lymphoid Leukemia Clinical Trial
Official title:
Prospective Study on the Incidence of Hepatitis B Virus Reactivation in Untreated Patients With Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide
In this study, we will evaluate the incidence of hepatitis B virus reactivation within the first 6 months of treatment with rituximab, standard chemotherapy and TAF in patients with diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive.
This is a prospective, multicenter, interventional, single arm, evaluating the incidence of hepatitis B virus (HBV) reactivation within the first 6 months treatment period in HBsAg positive patients treated for DLBCL/Chronic Lymphoid Leukemia with Rituximab, standard chemotherapy, and TAF. Approximate duration of the recruitment period based on the number of patients available The duration of the recruitment period has been estimated at 12 months. Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy. Then patients will be also observed for further12 months ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04515238 -
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
|
Phase 2 | |
| Completed |
NCT00406809 -
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03766763 -
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
|
Phase 2 | |
| Active, not recruiting |
NCT04608318 -
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
|
Phase 3 | |
| Active, not recruiting |
NCT04883749 -
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL
|
Phase 2 | |
| Active, not recruiting |
NCT00788684 -
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
|
Phase 1 | |
| Terminated |
NCT01518959 -
The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases
|
Phase 3 | |
| Completed |
NCT03787264 -
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL
|
Phase 2 | |
| Recruiting |
NCT03852407 -
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
|
Phase 2 | |
| Recruiting |
NCT05350826 -
Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia
|
N/A |